Otamixaban
From Self-sufficiency
| File:Otamixaban.svg | |
| File:Otamixaban 3D.png | |
| Systematic (IUPAC) name | |
|---|---|
|
methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate | |
| Identifiers | |
| CAS Number | 193153-04-7 |
| ATC code | none |
| PubChem | CID 5496659 |
| Chemical data | |
| Formula | C25H26N4O4 |
| Molar mass | 446.498 g/mol[[Script error: No such module "String".]] |
Otamixaban (INN) is an inhibitor of Factor Xa,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
See also
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This drug article relating to the blood and blood forming organs is a stub. You can help ssf by expanding it. |
- ↑ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID 17979700.
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Anticoagulants
- Blood and blood forming organ drug stubs
- 2Fix
